Literature DB >> 33982286

Pharmacokinetic characteristics of hydroxysafflor yellow A in normal and diabetic cardiomyopathy mice.

Rui Yao1,2, Yu Cao2, Ruibin Jiang1, Xuan Zhang1, Feng Li1, Siwang Wang2.   

Abstract

Hydroxysafflor yellow A (HSYA), a major active water-soluble component in Carthamus tinctorius L., is considered a potential antioxidant with protective effects against myocardial injury. However, its pharmacokinetic characteristics in normal and diabetic cardiomyopathy (DCM) mice remain unknown. This study was designed to investigate the differences in the pharmacokinetics of HSYA between normal and streptozotocin-induced DCM mice. HSYA in the mouse plasma was quantified using LC-MS/MS. Compared with the normal group, the DCM group showed a significantly higher area under the curve (AUC(0-t) , AUC(0-∞) ) value and peak plasma concentration, suggesting a higher uptake of HSYA in the DCM mice, and a significantly lower plasma clearance and apparent volume of distribution, suggesting slower elimination of HSYA in the DCM mice. The levels of serum superoxide dismutase and glutathione peroxidase were significantly higher, and malondialdehyde content was significantly lower in DCM mice than in normal mice, indicating the antioxidative stress effect of HSYA. Furthermore, the correlation analysis revealed that the serum HSYA content in the DCM mice significantly positively correlated with antioxidant enzyme levels. These results showed that the pharmacokinetics of HSYA changed significantly in the DCM mice, and this may improve the antioxidative stress effect of the drug.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  LC-MS/MS; diabetic cardiomyopathy; hydroxysafflor yellow A; pharmacokinetics

Year:  2021        PMID: 33982286     DOI: 10.1002/bmc.5173

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  1 in total

Review 1.  Pharmacological Activities of Safflower Yellow and Its Clinical Applications.

Authors:  Yan Chen; Meifeng Li; Jiayu Wen; Xiaoqi Pan; Zixin Deng; Junren Chen; Guanru Chen; Lei Yu; Yunli Tang; Gangmin Li; Xiaofang Xie; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-27       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.